HC Wainwright Analysts Increase Earnings Estimates for SABS

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – HC Wainwright increased their Q1 2025 EPS estimates for shares of SAB Biotherapeutics in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst E. White now expects that the company will earn ($1.14) per share for the quarter, up from their prior estimate of ($1.35). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.59) EPS, FY2026 earnings at ($3.59) EPS and FY2027 earnings at ($2.97) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.07). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.12 million.

Separately, Chardan Capital dropped their price objective on shares of SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics has an average rating of “Buy” and an average target price of $11.40.

SAB Biotherapeutics Trading Down 4.2 %

SABS opened at $1.13 on Thursday. The stock’s fifty day simple moving average is $1.78 and its 200 day simple moving average is $2.78. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $5.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $43,000. Kovitz Investment Group Partners LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter worth about $52,000. Diadema Partners LP bought a new stake in SAB Biotherapeutics in the 4th quarter valued at about $114,000. Geode Capital Management LLC grew its position in shares of SAB Biotherapeutics by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after purchasing an additional 12,692 shares in the last quarter. Finally, HB Wealth Management LLC increased its holdings in shares of SAB Biotherapeutics by 118.6% during the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after purchasing an additional 128,800 shares during the period. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.